PRESS RELEASE published on 03/10/2026 at 09:00, 13 days 4 hours ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics réalise une levée de fonds de près de 1,7 million d'euros pour développer des thérapies géniques innovantes. Annonce de succès pour l'opération Biopharmaceutique Levée De Fonds GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
BRIEF published on 03/09/2026 at 07:35, 14 days 5 hours ago GenSight Biologics: Update on Early Access Programs and the REVISED Study Gene Therapy GenSight Biologics Early Access Optic Neuropathy REVISED STUDY
BRIEF published on 03/09/2026 at 07:35, 14 days 5 hours ago GenSight Biologics fait le point sur ses programmes d'accès précoce et l'étude REVISE GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ® Étude REVISER Programmes D'accès Anticipé
BRIEF published on 03/09/2026 at 07:35, 14 days 5 hours ago GenSight Biologics : Point sur les Programmes d'Accès Précoce et l'Étude REVISE Thérapie Génique GenSight Biologics Neuropathie Optique Étude REVISE Accès Précoce
BRIEF published on 03/09/2026 at 07:35, 14 days 5 hours ago GenSight Biologics Updates on Early Access Programs and REVISE Study GenSight Biologics Leber Hereditary Optic Neuropathy Early Access Programs GS010/LUMEVOQ® REVISE Study
PRESS RELEASE published on 03/09/2026 at 07:30, 14 days 5 hours ago Informations privilégiées / Autres communiqués GenSight Biologics fait le point sur les programmes d'accès précoce de GS010/LUMEVOQ et sur l'étude REVISE en cours, avec des approbations en France, Israël et aux États-Unis Thérapie Génique GenSight Biologics GS010/LUMEVOQ Accès Précoce Dose REVISE
PRESS RELEASE published on 03/09/2026 at 07:30, 14 days 5 hours ago Inside Information / Other news releases GenSight Biologics provides updates on GS010/LUMEVOQ® early access programs and the ongoing REVISE study for treating LHON. Approvals, enrollments, and expansions announced in France, Israel, and the USA GenSight Biologics LHON Early Access Programs GS010/LUMEVOQ REVISE Study
BRIEF published on 02/18/2026 at 07:35, 1 month 5 days ago GenSight Biologics renforce son leadership réglementaire grâce à des nominations clés Thérapie Génique GenSight Biologics Maladies De La Rétine Nominations Stratégiques Leadership Réglementaire
BRIEF published on 02/18/2026 at 07:35, 1 month 5 days ago GenSight Biologics Strengthens Regulatory Leadership with Key Appointments Gene Therapy Strategic Appointments GenSight Biologics Retinal Diseases Regulatory Leadership
BRIEF published on 02/18/2026 at 07:35, 1 month 5 days ago GenSight Biologics Renforce son Équipe Réglementaire Affaires Réglementaires GenSight Biologics Thérapies Géniques Nominations Clés Essai Phase III
Published on 03/23/2026 at 12:32, 28 minutes ago Sinopec Announced 2025 Annual Results Annual Payout Ratio Reached 81%
Published on 03/23/2026 at 12:30, 30 minutes ago Digi Power X to Announce 2025 Year End Financial Results on March 31st
Published on 03/23/2026 at 12:30, 30 minutes ago High Tide Resources Announces Closing of Concurrent Non-Brokered Private Placements for Gross Proceeds of $8.3 Million
Published on 03/23/2026 at 12:20, 40 minutes ago Guanajuato Silver Adds Veteran Mine Operator to Board of Directors
Published on 03/23/2026 at 12:15, 45 minutes ago Snipp Interactive Secures US$3 Million Contract, Largest in Company History
Published on 03/23/2026 at 12:40, 20 minutes ago EQS-Adhoc: Ströer plans a dividend of €1.85 for fiscal year 2025 and approves a share buyback program of up to €50 million
Published on 03/23/2026 at 11:44, 1 hour 15 minutes ago Viromed Medical AG receives funding approval from the Federal Ministry of Research, Technology and Space for the development of cold plasma technology
Published on 03/23/2026 at 11:30, 1 hour 30 minutes ago EQS Group lance un module de gestion des risques pour faciliter la surveillance continue des risques liées aux données et à l’IA
Published on 03/23/2026 at 08:10, 4 hours 50 minutes ago Entrée en négociations exclusives de cession de la participation dans Winncare
Published on 03/20/2026 at 19:00, 2 days 18 hours ago AXA - Conditions for availability or consultation of information relating to AXA’s Shareholders’ Meeting of April 30, 2026
Published on 03/20/2026 at 19:00, 2 days 18 hours ago AXA - Modalités de mise à disposition ou de consultation des informations relatives à l’Assemblée Générale du 30 avril 2026
Published on 03/20/2026 at 18:15, 2 days 18 hours ago Publication of AXA’s 2025 Universal Registration Document
Published on 03/20/2026 at 18:15, 2 days 18 hours ago Mise à disposition du Document d’Enregistrement Universel 2025 d’AXA
